Plasma Metabolite Profiles in First Episode Psychosis: Exploring Symptoms Heterogeneity/Severity in Schizophrenia and Bipolar Disorder Cohorts

Autor(es)

Joaquim, Helena P. G. ^{[1, 2, 3]} ; Costa, Alana C. ^{[2, 3]} ; Talib, Leda L. ^{[2, 3]} ; Dethloff, Frederik ^[1] ; Serpa, Mauricio H. ^{[3, 4]} ; Zanetti, V, Marcus ; van de Bilt, Martinus ^{[2, 3]} ; Turck, Christoph W. ^[1]

Afiliação do(s) autor(es)

^[1] Max Planck Inst Psychiat, Dept Translat Res Psychiat, Munich - Germany

^[2] Univ Sao Paulo, Dept & Inst Psychiat, Lab Neurosci LIM 27, Med Sch, Sao Paulo - Brazil

^[3] Conselho Nacl Desenvolvimento Cientif & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria Inb, Sao Paulo - Brazil

^[4] V, Univ Sao Paulo, Dept & Inst Psychiat, Lab Psychiat Neuroimaging LIM 21, Med Sch, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: FRONTIERS IN PSYCHIATRY; v. 11, JUN 5 2020.
• Citações Web of Science: 0

Resumo

Introduction The first symptoms of psychosis are frequently shared amongst several neuropsychiatry disorders, which makes the differentiation by clinical diagnosis challenging. Early recognition of symptoms is important in the management of psychosis. Therefore, the implementation of molecular biomarkers will be crucial for transforming the currently used diagnostic and therapeutic approach, improving insights into the underlying biological processes and clinical management. Objectives To define a set of metabolites that supports diagnosis or prognosis of schizophrenia (SCZ) and bipolar disorder (BD) at first onset psychosis. Methods Plasma samples from 55 drug-naive patients, 28 SCZ and 27 BD, and 42 healthy controls (HC). All participants underwent a seminaturalistic treatment regimen, clinically evaluated on a weekly basis until achieving clinical remission. All clinical or sociodemographic aspects considered for this study were equivalent between the groups at first-onset psychosis time point. The plasma samples were analyzed by untargeted liquid chromatography-tandem mass spectrometry (LC-MS/MS) using reversed-phase and hydrophilic interaction chromatography. The acquired molecular features were analyzed with MetaboAnalyst. Results We identified two patient groups with different metabolite profiles. Both groups are composed of SCZ and BD patients. We found differences between these two groups regarding general symptoms of PANSS score after remission (p = 0.008), and the improvement of general symptoms (delta of the score at remission minus the baseline) (-0.50 vs. -0.33, p = 0.019). Conclusion Our results suggest that plasma metabolite profiles cluster clinical remission phenotypes based on PANSS general psychopathology scores. (AU)

• Processo FAPESP: 14/50873-3 - INCT 2014: Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBioN)
• Beneficiário: Wagner Farid Gattaz
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 14/20913-3 - Determinação de fosfolípides plasmáticos nas doenças neuropsiquiátricas
• Beneficiário: Alana Caroline Costa
• Modalidade de apoio: Bolsas no Brasil - Mestrado